| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2019-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102212792-B1 |
| titleOfInvention |
Combination therapy of anticancer drugs and aripiprazole |
| abstract |
The present invention relates to an anticancer adjuvant comprising aripiprazole as an active ingredient, wherein aripiprazole has an effect of enhancing sensitivity to an anticancer agent, and when administered in combination with an anticancer agent, apoptosis of cancer cells or multidrug resistant cancer cells is increased. By doing so, it can be especially useful for the treatment of anticancer drug-resistant cancer. |
| priorityDate |
2019-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |